Cell Lines

mutant and normal

TM
X-MAN Catalogue
isogenic human cell lines
Issue: Q1, 2011

www.horizondiscovery.com
 New Cell Lines

Cell Line Gene Genotype Genotype

Genes tagged at endogenous locus

HCT116 APC SBP-3xFlag
HCT116 Asf1 CBP-3xFlag
HCT116 Baz2a CBP-3xFlag
HCT116 Bmi1 CBP-3xFlag
RKO B-RAF mutant allele tagged with SBP-Flag
RKO B-RAF wild type allele tagged with SBP-Flag
DLD-1 CHD2 SBP-3xFlag
DLD-1 CHD7 CBP-3xFlag
DLD-1 CHD8 SBP-3xFlag
RKO DNMT1 CBP-3xFlag
DLD-1 DNMT3b CBP-3xFlag
HCT116 Dot1l CBP-3xFlag
HCT116 E2f1 CBP-3xFlag
HCT116 Eed CBP-3xFlag
HCT116 EzH2 CBP-3xFlag
HCT116 IDH1 SBP-3xFlag
HCT116 Kaiso SBP-3xFlag
RKO Mre11 CBP-3xFlag
LoVo Mre11 CBP-3xFlag
HCT116 Mrgbp CBP-3xFlag
DLD-1 PTPN14 CBP-3xFlag
HCT116 Rcor2 CBP-3xFlag
HCT116 Sirt6 CBP-3xFlag
DLD-1 STAT3 CBP-3xFlag
HCT116 Trim37 CBP-3xFlag
HCT116 UHRF1 SBP-3xFlag
HCT116 Zcchc4 CBP-3xFlag

Note: CBP-3xFlag calmodulin binding peptide (CBP)-3xFlag

SBP-3xFlag streptavidin binding protein (SBP)-3xFlag

Additional Cell Lines

DLD-1 HAUSP/USP7 knock-out
HCT116 Kaiso knock-out
HCT116 BCAR1/p130CAS (Y128F)
RKO BCAR1/p130CAS (Y128F)
DLD-1 STAT3 knock-out
HCT116 STAT3 (Y705F)
RKO STAT3 (Y705F)
DLD-1 STAT3 (Y705F)
DLD-1 Paxillin (Y88F)
HCT116 Paxillin (Y88F)

13www.horizondiscovery.com 5
www.horizondiscovery.com
 Single mutated cancer gene panel

Catalogue No. Cell line Genotype Main Characteristics

HD100-001 HME EGFR (del E746-A750) Heterozygous activating kinase domain mutation
HD100-002 HME PI3Kα (H1047R) Heterozygous activating kinase domain mutation
HD100-003 HME PI3Kα (E545K) Heterozygous activating kinase domain mutation
HD100-004 HME K-Ras (G13D) Heterozygous GTPase mutant leading to constitutive Ras-signalling
HD100-005 HME B-Raf (V600E) Heterozygous activating kinase domain mutation

HD101-002 MCF10A PI3Kα (E545K) Heterozygous activating hinge domain mutation

HD101-004 MCF10A K-Ras (G12V) Heterozygous GTPase mutant leading to constitutive Ras-signalling
HD101-005 MCF10A p53 null Homozygous tumour suppressor knock-out of exon 2
HD101-006 MCF10A PTEN null Homozygous tumour suppressor knock-out of exon 2
HD101-007 MCF10A AKT1 (E17K) Heterozygous activating PH domain mutation
HD101-008 MCF10A B-Raf (V600E) Heterozygous knock-in of activating mutation; Neo resistant
HD101-009 MCF10A β-Catenin (T41A) Heterozygous knock-in of activating mutation; Neo resistant
HD101-010 MCF10A EGFR (del E746-A750) Heterozygous activating kinase domain mutation
HD101-011 MCF10A PI3Kα (H1047R) Heterozygous activating kinase domain mutation
new HD101-012 MCF10A B-Raf (V600E) Heterozygous knock-in of activating mutation; Neo sensitive
new HD101-013 MCF10A IDH1 (R132H) Heterozygous knock-in of activating mutation; Neo resistant

HD102-001 RPE-1 PI3Kα (H1047R) Heterozygous activating kinase domain mutation

HD102-002 RPE-1 PI3Kα (E545K) Heterozygous activating hinge domain mutation
HD102-003 RPE-1 EGFR (del E746-A750) Heterozygous activating kinase domain mutation

HD103-001 SW48 PI3Kα (E545K) Heterozygous activating hinge domain mutation

HD103-002 SW48 K-Ras (G13D) Heterozygous GTPase mutant leading to constitutive Ras-signalling
HD103-003 SW48 B-Raf (V600E) Heterozygous activating kinase domain mutation
HD103-004 SW48 p53 null Homozygous tumour suppressor knock-out
HD103-005 SW48 PI3Kα (H1047R) Heterozygous knock-in of activating mutation
HD103-006 SW48 K-Ras (G12C) Heterozygous GTPase mutant leading to constitutive Ras-signalling
new HD103-007 SW48 K-Ras (G12V) Heterozygous GTPase mutant leading to constitutive Ras-signalling
new HD103-008 SW48 p53 (R273H) Heterozygous knock-in of dominant negative mutation (R273H)
new HD103-009 SW48 K-Ras (G12A) Heterozygous GTPase mutant leading to constitutive Ras-signalling
new HD103-010 SW48 K-Ras (G12R) Heterozygous GTPase mutant leading to constitutive Ras-signalling
new HD103-011 SW48 K-Ras (G12D) Heterozygous GTPase mutant leading to constitutive Ras-signalling
new HD103-012 SW48 PTEN null Homozygous tumour suppressor knock-out
new HD103-013 SW48 K-Ras (G12S) Heterozygous GTPase mutant leading to constitutive Ras-signalling

HD104-001 HCT116 p53 null Homozygous tumour suppressor knock-out

HD104-002 HCT116 p53 (R248W) Heterozygous knock-in of mutant tumour supressor
HD104-003 HCT116 p53 (R248W/-) Knock-in of mutant tumour supressor and knock-out of wild type allele
HD104-004 HCT116 PTEN null Homozygous tumour suppressor knock-out
HD104-005 HCT116 SMAD4 null Homozygous tumour suppressor knock-out
HD104-006 HCT116 MLH1 (wild type knock-in) Heterozygous knock-in of wild-type gene in mutant parent cells
HD104-007 HCT116 PI3Kα (H1047R knock-out) Knock-out of mutant allele (H1047R) in heterozygous parental cells
HD104-008 HCT116 K-Ras (G13D knock-out) Knock-out of mutant allele (G13D) in heterozygous parental cells; GFP
version available
HD104-009 HCT116 β-Catenin (
45 knock-out) Knock-out of mutant allele (
45) in heterozygous parental cells
HD104-010 HCT116 β-Catenin (wild type knock-out) Knock-out of wild type allele in heterozygous parental cells
HD104-011 HCT116 K-Ras (wild type knock-out) Knock-out of wild type allele in heterozygous parental cells
HD104-012 HCT116 PI3Kα (wild type knock-out) Knock-out of wild type allele in heterozygous parental cells
new HD104-013 HCT116 IDH1 (R132H) Heterozygous knock-in of activating mutation; Neo resistant

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

www.horizondiscovery.com 514
 Single mutated cancer gene panel

Catalogue No. Cell line Genotype Main Characteristics

HD105-001 DLD-1 PI3Kα (E545K knock-out) Knock-out of mutant allele in heterozygous parental cells
HD105-002 DLD-1 K-Ras (G13D knock-out) Knock-out of mutant allele in heterozygous parental cells; YFP version
available
HD105-003 DLD-1 p53 (S241F/silenced) Parental DLD-1 is mutant/silenced
HD105-004 DLD-1 p53 (-/silenced) Knock-out of mutant allele (S241F) (2nd Allele still silenced)
HD105-005 DLD-1 p53 (wild type/silenced) Knock-in of wild type p53 into mutant allele (2nd Allele still silenced)
HD105-007 DLD-1 BRCA2 null (del. exon 11/del. exon 11) Knock-out of DNA repair 'caretaker' gene (bi-allelic null)
HD105-008 DLD-1 BRCA2 null (del. exon 11/Y3308X) Knock-out of DNA repair 'caretaker' gene (null/knock-in of inactivating
point mutant )
HD105-009 DLD-1 BRCA2 null (del. exon 11/S3291E) Knock-out of DNA repair 'caretaker' gene (null/knock-in hypomorphic
point mutation)
HD105-010 DLD-1 ATR (A2101G) Homozygous hypomorphic ATR mutation (Seckel); p53 mutant
background
HD105-011 DLD-1 K-Ras (wild type knock-out) Knock-out of wild type allele in heterozygous parental cells
HD105-012 DLD-1 PI3Kα (wild type knock-out) Knock-out of wild type allele in heterozygous parental cells
new HD105-013 DLD-1 p53 (S241F/-) Knock-out of silenced p53 allele; Neo resistant. Replaces HD105-006

HD106-001 RKO p53 (R248W) Knock-in of mutant tumour supressor

HD106-002 RKO p53 null Tumour suppressor knock-out
HD106-003 RKO B-Raf (V600E knock-out) Knock-out of mutant allele in triploid parental cells (+/-/-)
HD106-004 RKO B-Raf (wild type knock-out) Wild type allele knock-out in triploid parental cells (V600E/-/-)

HD 107-001 VACO 432 B-Raf (V600E knock-out) Knock-out of mutant allele in heterozygous parental cells
HD 107-002 VACO 432 B-Raf (wild type knock-out) Knock-out of wild type allele in heterozygous parental cells

HD108-001 KMS11 MMSET (NTKO) Knock-out of non-translocated MMSET allele in a heterozygous Multiple
Myeloma line
HD108-002 KMS11 MMSET (TKO) Knock-out of translocated MMSET allele in a heterozygous Multiple
Myeloma line

HD109-001 Panc 04.03 MKK4 null Knock-out of MMK4 (MAP2K4) in Pancreatic cell line

Double mutated cancer gene panel

Catalogue No. Cell line Genotype Main Characteristics

HD 200-001 HME PI3Kα (H1047R) & EGFR (del E746-A750) Double knock-in of two cancer genes
HD 200-002 HME EGFR (del E746-A750) & B-Raf (V600E) Double knock-in of two cancer genes
HD 200-003 HME K-Ras (G13D) & PI3Kα (H1047R) Double knock-in of two cancer genes

HD 201-001 MCF10A PI3Kα (H1047R) & EGFR (del E746-A750) Double knock-in of two cancer genes
HD 201-002 MCF10A PI3Kα (E545K) & K-Ras (G12V) Double knock-in of two cancer genes
HD 201-003 MCF10A PI3Kα (H1047R) & K-Ras (G12V) Double knock-in of two cancer genes

HD 202-001 DLD-1 ATR (A2101G) & wild type p53 Homozygous hypomorphic ATR mutation (Seckel) and
heterozygous knock-in of wild type p53 (wild type/silenced)

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

615 www.horizondiscovery.com
 Researcher
Cancer associated/modifier gene panel

Catalogue No. Cell line Genotype (Knock Outs, unless otherwise stated)

HD R00-001 DLD-1 AKT1 (-/- )

HD R00-002 DLD-1 AKT2 (-/-)
HD R00-003 DLD-1 AKT1 (-/-) & AKT2 (-/-)
HD R00-004 DLD-1 B-Raf (-/-)
HD R00-005 DLD-1 CDC4 (-/-)
HD R00-006 DLD-1 CDC4 (+/-)
HD R00-007 DLD-1 CHK1 knock-out (S317A heterozygous knock-in)
HD R00-008 DLD-1 CHK1 knock-out (S317A/S317A double knock-in)
HD R00-009 DLD-1 Dicer (-/-)
HD R00-010 DLD-1 Inducible mutant p53
HD R00-011 DLD-1 Inducible mutant p73
HD R00-012 DLD-1 Inducible wild type p53
HD R00-013 DLD-1 Inducible wild type p73
HD R00-014 DLD-1 Inducible PUMA
HD R00-015 DLD-1 Inducible GFP
HD R00-016 DLD-1 Inducible TbRII
HD R00-017 DLD-1 MEK1 (-/-)
HD R00-018 DLD-1 MEK2 (-/-)
HD R00-019 DLD-1 MEK2 (+/-)
HD R00-020 DLD-1 p21 (-/-)
HD R00-021 DLD-1 MTAP (-/-)
HD R00-022 DLD-1 TCF4 Inducible Luciferase
HD R00-023 DLD-1 XIAP (-/-)
HD R00-024 DLD-1 GLUT1 (-/-)
new HD R00-025 DLD-1 ATR (A2101G/+) & p53 wild type knock-in (wild type/silenced)
new HD R00-026 DLD-1 CHK1 heterozygous (+/-) & p53 wild type knock-in (wild type/silenced)
new HD R00-027 DLD-1 CHK1 heterozygous (+/-) in p53 mutant background

HD R01-001 HACAT DEC1 (-/-)

HD R01-002 HACAT DEC1 (+/-)

HD R02-001 HCT116 14-3-3 sigma (-/-)

HD R02-002 HCT116 14-3-3 sigma (+/-)
HD R02-003 HCT116 14-3-3 sigma (-/-) & p21 (-/-)
HD R02-004 HCT116 AKT1 (-/-)
HD R02-005 HCT116 AKT2 (-/-)
HD R02-006 HCT116 AKT1 (-/-) & AKT2 (-/-)
HD R02-007 HCT116 APOC1 (-/-)
HD R02-008 HCT116 BAX (-/-)
HD R02-009 HCT116 BAX (+/-)
HD R02-010 HCT116 BAX (-/-) & p21 (-/-)
HD R02-011 HCT116 BLM (-/-)
HD R02-012 HCT116 B-Raf (-/-)
HD R02-013 HCT116 CDC4 (-/-)
HD R02-014 HCT116 CDC4 (+/-)
HD R02-015 HCT116 CDK2 (-/-)
HD R02-016 HCT116 CDK2 (-/-) & p53 knock-out (-/-)
HD R02-017 HCT116 CHK2 (-/-)
HD R02-018 HCT116 CHK2 (-/-) & p53 knock-out (-/-)
HD R02-019 HCT116 Dicer (-/-)
HD R02-020 HCT116 DNMT1 (-/-)
HD R02-021 HCT116 DNMT1 (+/-)
HD R02-022 HCT116 DNMT1 (-/-) & DNMT3b (-/-) (DKO)
HD R02-023 HCT116 DNMT3b (-/-)

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

8 www.horizondiscovery.com 16
www.horizondiscovery.com
 Researcher
Cancer associated/modifier gene panel

Catalogue No. Cell line Genotype (Knock Outs, unless otherwise stated)

HD R02-024 HCT116 DNMT1 (-/-) & DNMT3b (-/-) & p16 (mutant/-) (TKO)
HD R02-025 HCT116 DNMT1 (-/-) & DNMT3b (-/-) & p16 (-/wild type) (TKO)
HD R02-026 HCT116 DNMT1 (+/-) & DNMT3b (-/-) & p16 (mutant/-) (TKO)
HD R02-027 HCT116 DNMT1(+/-) & DNMT3a (+/-) & DNMT3b (-/-) & p16 (mutant/-) (TKO)
HD R02-028 HCT116 HAUSP (-/-)
HD R02-029 HCT116 HAUSP (+/-)
HD R02-030 HCT116 MEK1 (-/-)
HD R02-031 HCT116 MEK2 (-/-)
HD R02-032 HCT116 MEK2 (+/-)
HD R02-033 HCT116 MTAP (-/-)
HD R02-034 HCT116 p16 (wild type allele knock-out)
HD R02-035 HCT116 p21 (-/-)
HD R02-036 HCT116 p21(+/-)
HD R02-037 HCT116 p53 (+/-)
HD R02-038 HCT116 PPAR delta (-/-)
HD R02-039 HCT116 PPAR delta (+/-)
HD R02-040 HCT116 PUMA (-/-)
HD R02-041 HCT116 PUMA (-/-) & p21 (-/-)
HD R02-042 HCT116 K-Ras (wild type allele knock-out; GFP/YFP versions available)
HD R02-043 HCT116 Securin (-/-)
HD R02-044 HCT116 Securin (+/-)
HD R02-045 HCT116 Smac/Diablo (-/-)
HD R02-046 HCT116 SMAD4 (+/-)
HD R02-047 HCT116 XIAP (-/-)
HD R02-048 HCT116 DNA-PKcs (+/-)
HD R02-049 HCT116 DNA-PKcs (-/-)
HD R02-050 HCT116 DNA-PKcs (-/-) & DNA-PKcs cDNA over-expression
HD R02-051 HCT116 DNA-PKcs (-/-) & Ku70 (+/NEO)
HD R02-052 HCT116 HPRT (-/0)
HD R02-053 HCT116 Ku70 (+/-)
HD R02-054 HCT116 Ku86 (+/flox)
HD R02-055 HCT116 Ku86 (-/flox)
HD R02-056 HCT116 Ku86 (-/flox) & LIGIV (+/-)
HD R02-057 HCT116 Ku86 (-/flox) & LIGIV (-/-)
HD R02-058 HCT116 Ku86 (-/flox) & RAD54B (+/+/-)
HD R02-059 HCT116 Ku86 (-/flox) & RAD54B (+/-/-)
HD R02-060 HCT116 LIGIII (+/flox)
HD R02-061 HCT116 LIGIII (-/flox)
HD R02-062 HCT116 LIGIV (+/-)
HD R02-063 HCT116 LIGIV (-/-)
HD R02-064 HCT116 LIGIV (-/-) & Ku70 (+/NEO)
HD R02-065 HCT116 LIGIV (-/-) & RAD54B (+/+/-)
HD R02-066 HCT116 LIGIV (-/-) & RAD54B (+/-/-)
HD R02-067 HCT116 XLF (+/-)
HD R02-068 HCT116 XLF (-/-)
HD R02-069 HCT116 XLF (-/-) & XLF cDNA over-expression
HD R02-070 HCT116 XLF (-/-) & XLF cDNA over-expression (L115A)
HD R02-071 HCT116 XLF (-/-) & XLF cDNA over-expression (L179A)
HD R02-072 HCT116 XLF (-/-) & XLF cDNA over-expression (R57G)
HD R02-073 HCT116 XLF (-/-) & XLF cDNA over-expression (C123R)
HD R02-074 HCT116 XLF (-/-) & XLF cDNA over-expression (R178X)
HD R02-075 HCT116 XRCC4 (+/-)
HD R02-076 HCT116 XRCC4 (-/-)
new HD R02-077 HCT116 Chk1 heterozygous (+/-) in p53 wild type background
new HD R02-078 HCT116 Chk1 heterozygous (+/-) in p53 null background
new HD R02-079 HCT116 DNMT1 (-/-) & DNMT3B (-/-) (retains methylation)

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

17www.horizondiscovery.com 9
www.horizondiscovery.com
 Researcher
Cancer associated/modifier gene panel

Catalogue No. Cell line Genotype (Knock Outs, unless otherwise stated)

HD R03-001 HT-29 Inducible APC

HD R03-002 HT-29 Inducible beta-galactosidase

HD R05-001 RKO Dicer (-/-)

HD R05-002 RKO FANCG (+/-)
HD R05-003 RKO FANCC (+/+/-)
HD R05-004 RKO FANCC (+/-/-)
HD R05-005 RKO FANCG (-/-)
HD R05-006 RKO FANCC (-/-/-)
HD R05-007 RKO MEK2 (-/-)
HD R05-008 RKO MEK2 (+/-)
HD R05-009 RKO p53 (+/-)
HD R05-010 RKO MEK1 (-/-)
HD R05-011 RKO GLUT1 (-/-)
HD R05-012 RKO B-Raf (V600E/+/-)

new HD R06-001 SW48 p53 (+/-)

HD R07-001 VACO 432 MEK1 (-/-)

HD R07-002 VACO 432 MEK2 (-/-)
HD R07-003 VACO 432 MEK2 (+/-)

HD R08-001 NALM-6 DNA-PKcs (+/-)

HD R08-002 NALM-6 Ku70 (+/-)
HD R08-003 NALM-6 Ku86 (+/-)

HD R09-001 BJ DNA-PKcs (+/-)

HD R10-001 RPE Artemis (+/-)

HD R10-002 RPE CCR5 (+/-)
HD R10-003 RPE DNA-PKcs (+/-)
HD R10-004 RPE XRCC4 (+/-)

new HD R11-001 MCF10A PTEN (+/-)

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

10www.horizondiscovery.com 18
www.horizondiscovery.com
 DNArepair
DNA repair enzyme/modifier gene panel

Catalogue No. Cell line Genotype

HD101-005 MCF10A p53 null

HD103-004 SW48 p53 null
HD103-008 SW48 p53 (R273H)
HD104-001 HCT116 p53 null
HD104-002 HCT116 p53 (R248W)
HD104-003 HCT116 p53 (R248W/-)
HD R02-037 HCT116 p53 (+/-)
HD105-003 DLD-1 p53 (S241F/silenced)
HD105-004 DLD-1 p53 (-/silenced)
HD105-005 DLD-1 p53 (wild type/silenced)
HD105-013 DLD-1 p53 (S241F/-)
HD106-001 RKO p53 (R248W)
HD106-002 RKO p53 null

HD105-007 DLD-1 BRCA2 null (del. exon 11/del. exon 11)

HD105-008 DLD-1 BRCA2 null (del. exon 11/Y3308X)
HD105-009 DLD-1 BRCA2 null (del. exon 11/S3291E)

HD105-010 DLD-1 ATR (A2101G)

HD 202-001 DLD-1 ATR (A2101G) & wild type p53
HD R00-025 DLD-1 ATR (A2101G/+) & p53 wild type knock-in (wild type/silenced)

HD R00-007 DLD-1 CHK1 knock-out (S317A heterozygous knock-in)

HD R00-008 DLD-1 CHK1 knock-out (S317A/S317A double knock-in)
HD R00-026 DLD-1 CHK1 heterozygous (+/-) & p53 wild type knock-in (wild type/silenced)
HD R00-027 DLD-1 CHK1 heterozygous (+/-) in p53 mutant background
HD R02-077 HCT116 CHK1 heterozygous (+/-) in p53 wild type background
HD R02-078 HCT116 CHK1 heterozygous (+/-) in p53 null background

HD R02-017 HCT116 CHK2 (-/-)

HD R02-018 HCT116 CHK2 (-/-) & p53 knock-out (-/-)

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

19www.horizondiscovery.com 11
www.horizondiscovery.com
 DNArepair
DNA repair enzyme/modifier gene panel

Catalogue No. Cell line Genotype

HD R02-011 HCT116 BLM (-/-)

HD104-006 HCT116 MLH1 (wild type knock-in)
HD R02-048 HCT116 DNA-PKcs (+/-)
HD R02-049 HCT116 DNA-PKcs (-/-)
HD R02-050 HCT116 DNA-PKcs (-/-) & DNA-PKcs cDNA over-expression
HD R02-051 HCT116 DNA-PKcs (-/-) & Ku70 (+/NEO)
HD R02-053 HCT116 Ku70 (+/-)
HD R02-054 HCT116 Ku86 (+/flox)
HD R02-055 HCT116 Ku86 (-/flox)
HD R02-056 HCT116 Ku86 (-/flox) & LIGIV (+/-)
HD R02-057 HCT116 Ku86 (-/flox) & LIGIV (-/-)
HD R02-058 HCT116 Ku86 (-/flox) & RAD54B (+/+/-)
HD R02-059 HCT116 Ku86 (-/flox) & RAD54B (+/-/-)
HD R02-060 HCT116 LIGIII (+/flox)
HD R02-061 HCT116 LIGIII (-/flox)
HD R02-062 HCT116 LIGIV (+/-)
HD R02-063 HCT116 LIGIV (-/-)
HD R02-064 HCT116 LIGIV (-/-) & Ku70 (+/NEO)
HD R02-065 HCT116 LIGIV (-/-) & RAD54B (+/+/-)
HD R02-066 HCT116 LIGIV (-/-) & RAD54B (+/-/-)
HD R02-067 HCT116 XLF (+/-)
HD R02-068 HCT116 XLF (-/-)
HD R02-069 HCT116 XLF (-/-) & XLF cDNA over-expression
HD R02-070 HCT116 XLF (-/-) & XLF cDNA over-expression (L115A)
HD R02-071 HCT116 XLF (-/-) & XLF cDNA over-expression (L179A)
HD R02-072 HCT116 XLF (-/-) & XLF cDNA over-expression (R57G)
HD R02-073 HCT116 XLF (-/-) & XLF cDNA over-expression (C123R)
HD R02-074 HCT116 XLF (-/-) & XLF cDNA over-expression (R178X)
HD R02-075 HCT116 XRCC4 (+/-)
HD R02-076 HCT116 XRCC4 (-/-)

All cell lines available OTS on simple licensing or collaborative terms. Custom cell line development and compound screening services also available.

www.horizondiscovery.com 20
15
In Development

Cell line Genotype Main Characteristics





!





23(/.2
3+
.2&(7.9&7.2,
187&7.32

)*0




!



187&27
4
! %

38'0*
/23(/.2
3+
)31.2&27
2*,&7.9*
4




!
  

!&+
$ 

38'0*
/23(/.2




!&6

$

#





38'0*
/23(/.2




"1337-*2*)
%


23(/.2
3+
&(7.9&7.2,
187&7.32




<&7*2.2





23(/.2
3+
&(7.9&7.2,
187&7.32




!
!



23(/.2
3+
&(7.9&7.2,
187&7.32




!
# 



23(/.2
3+
6*(32)&5;
5*6.67&2(*
187&7.32




!

"



23(/.2
3+
&(7.9&7.2,
187&7.32





 



23(/.2
3+
&(7.9&7.2,
187&7.32




!&6

#



23(/.2
3+
&(7.9&7.2,
187&7.32

"% 


!
# 



23(/.2
3+
5*6.67&2(*
187&7.32

"% 


!
!



23(/.2
3+
&(7.9&7.2,
187&7.32
"% 


!





23(/.2
3+
&(7.9&7.2,
187&7.32
"% 


!
"




!*9*56.32
3+
*:.67.2,
&(7.9&7.2,
187&7.32
"% 


!
 #
)*0



23(/.2
3+
&(7.9&7.2,
187&7.32
"% 


!
 #
)*0



23(/.2
3+
&(7.9&7.2,
187&7.32
"% 


!
 ")*0



23(/.2
3+
&(7.9&7.2,
187&7.32
"% 


"1337-*2*)
%


23(/.2
3+
&(7.9&7.2,
187&7.32
"% 


!&6
 




23(/.2
3+
&(7.9&7.2,
187&7.32

00
(*00
0.2*6
&9&.0&'0*
>#"
32
6.140*
0.(*26.2,
35
(300&'35&7.9*
7*516=

86731
(*00
0.2*
)*9*0341*27
&2)
(314382)
6(5**2.2,
6*59.(*6
&063
&9&.0&'0*=

21
12 www.horizondiscovery.com
 300+ ready to ship isogenic cell lines including p53, K-Ras, B-Raf, PI3Kα and EGFR

Custom cell lines with your endogenous DNA sequence of interest; SNPs, knock-ins and knock-outs

Compound screening, standard and bespoke assay development (in vitro and in vivo)

Genomic standards and reference materials for companion diagnostics

If you require any further information or wish to discuss your requirements, please call us on
+44 (0) 1223 655583 (UK) or +1 617 4184190 (USA) or e-mail xman@horizondiscovery.com

For more information please contact:

Horizon Discovery Ltd.
Building 7300 IQ Cambridge Waterbeach Cambridge CB25 9TL United Kingdom
Tel: +44 (0)1223 655583 - Fax: +44 (0)1223 862240 - E mail: xman@horizondiscovery.com

© 2010, Horizon Discovery Ltd. X-MAN and X-MAN logo are registered
trade marks of Horizon Discovery Ltd.